SNY Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of 36.7% compared to Sanofi's net margin of -1.89%. Sanofi's return on equity of 12.45% beat BioNTech SE's return on equity of -3.01%.

Sanofi has a consensus price target of $57.68, signalling upside risk potential of 25.01%. On the other hand BioNTech SE has an analysts' consensus of $139.76 which suggests that it could grow by 29.46%. Given that BioNTech SE has higher upside potential than Sanofi, analysts believe BioNTech SE is more attractive than Sanofi.

Sanofi has a beta of 0.455, which suggesting that the stock is 54.501% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.488, suggesting its more volatile than the S&P 500 by 48.755%.

Sanofi has a quarterly dividend of $2.20 per share corresponding to a yield of 4.76%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi pays 66.53% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are larger than BioNTech SE quarterly revenues of $1.8B. Sanofi's net income of $4.5B is higher than BioNTech SE's net income of -$33.5M. Notably, Sanofi's price-to-earnings ratio is 19.33x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.28x versus 7.34x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 36.7% compared to Sanofi's net margin of -121.83%. Sanofi's return on equity of 12.45% beat Moderna, Inc.'s return on equity of -29.19%.

Sanofi has a consensus price target of $57.68, signalling upside risk potential of 25.01%. On the other hand Moderna, Inc. has an analysts' consensus of $41.60 which suggests that it could fall by -10.73%. Given that Sanofi has higher upside potential than Moderna, Inc., analysts believe Sanofi is more attractive than Moderna, Inc..

Sanofi has a beta of 0.455, which suggesting that the stock is 54.501% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.821%.

Sanofi has a quarterly dividend of $2.20 per share corresponding to a yield of 4.76%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi pays 66.53% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are larger than Moderna, Inc. quarterly revenues of $678M. Sanofi's net income of $4.5B is higher than Moderna, Inc.'s net income of -$826M. Notably, Sanofi's price-to-earnings ratio is 19.33x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.28x versus 9.32x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novavax, Inc. has a net margin of 36.7% compared to Sanofi's net margin of -287.29%. Sanofi's return on equity of 12.45% beat Novavax, Inc.'s return on equity of --.

Sanofi has a consensus price target of $57.68, signalling upside risk potential of 25.01%. On the other hand Novavax, Inc. has an analysts' consensus of $12.89 which suggests that it could grow by 48.32%. Given that Novavax, Inc. has higher upside potential than Sanofi, analysts believe Novavax, Inc. is more attractive than Sanofi.

Sanofi has a beta of 0.455, which suggesting that the stock is 54.501% less volatile than S&P 500. In comparison Novavax, Inc. has a beta of 2.583, suggesting its more volatile than the S&P 500 by 158.251%.

Sanofi has a quarterly dividend of $2.20 per share corresponding to a yield of 4.76%. Novavax, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi pays 66.53% of its earnings as a dividend. Novavax, Inc. pays out -- of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are larger than Novavax, Inc. quarterly revenues of $70.4M. Sanofi's net income of $4.5B is higher than Novavax, Inc.'s net income of -$202.4M. Notably, Sanofi's price-to-earnings ratio is 19.33x while Novavax, Inc.'s PE ratio is 4.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.28x versus 1.38x for Novavax, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 36.7% compared to Sanofi's net margin of 21.74%. Sanofi's return on equity of 12.45% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Sanofi has a consensus price target of $57.68, signalling upside risk potential of 25.01%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $868.04 which suggests that it could grow by 9.58%. Given that Sanofi has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Sanofi is more attractive than Regeneron Pharmaceuticals, Inc..

Sanofi has a beta of 0.455, which suggesting that the stock is 54.501% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Sanofi has a quarterly dividend of $2.20 per share corresponding to a yield of 4.76%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.44% to investors and pays a quarterly dividend of $0.88 per share. Sanofi pays 66.53% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Sanofi's net income of $4.5B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Sanofi's price-to-earnings ratio is 19.33x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 19.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.28x versus 6.00x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.